- ►nih.gov - Free from Publisher RC Tripathi, BJ Tripathi - British Journal of Ophthalmology, 2005 - bjo.bmj.com Improvements in techniques, instru- mentation, and intraocular lens design
appear to have been associated with declining rates of posterior capsule
opacification following cataract sur- gery.1 While morbidity associated ... Cited by 1 - Related articles - BL Direct - All 8 versions
JV Forrester, J Williamson - Transactions of the ophthalmological societies of the …, 1974 - ncbi.nlm.nih.gov 1: Trans Ophthalmol Soc U K. 1974 Jul;94(2):583-6. Lytic therapy in vitreous
haemorrhage. Forrester JV, Williamson J. Mesh Terms ... Cited by 5 - Related articles
[CITATION] Tissue plasminogen activator treatment of failing glaucoma filtering surgery. ARVO Abstract
RC Tripathi, BJ Tripathi, S Bornstein, E … - Drug Development Research, 1992 - interscience.wiley.com We treated 10 patients with tissue plasminogen activator (tPA) for complications
that threatened the successful outcome of anterior segment surgery for glaucoma
and/or cataract, and that endangered the structural and functional ... Cited by 3 - Related articles - BL Direct - All 2 versions
N Georgiadis, K Boboridis, N Halvatzis, N … - Journal of Cataract & Refractive Surgery, 2003 - Elsevier The study comprised routine surgical and postoperative cases selected in a
nonrandomized fashion. Low-dose tPA infusion (0.2 mL of 125 μg/mL) was
administered through a side-port in the anterior chamber in 25 patients ... Cited by 9 - Related articles - All 7 versions
T Starck, L Hopp, KS Held, LM Marouf, RW … - Journal of cataract and refractive surgery, 1995 - ncbi.nlm.nih.gov Tissue plasminogen activator (tPA) has been used to treat severe postcataract
and vitrectomy fibrinous membranes, but intraocular bleeding has occurred with
doses of 25 micrograms or higher. We report three patients, one with ... Cited by 9 - Related articles - BL Direct - All 2 versions
- ►iovs.org H Lei, P Hovland, G Velez, A Haran, D … - Investigative ophthalmology & visual science, 2007 - ARVO PURPOSE. Proliferative vitreoretinopathy (PVR) is a disorder characterized by
the formation of cellular membranes on both surfaces of the retina and within
the vitreous cavity. It occurs in 5% to 10% of patients who undergo retinal ... Cited by 9 - Related articles - BL Direct - All 3 versions
G Wollensak, JH Meyer, KU Löffler, J Funk - Klinische Monatsblätter für Augenheilkunde, 1996 - ncbi.nlm.nih.gov BACKGROUND: In recent years TPA (tissue-plasminogen activator) has been
increasingly and successfully used for the treatment of severe, postoperative
fibrin reaction in the anterior chamber. So far no serious side effects of ... Cited by 9 - Related articles
O Textorius, S STENKULA - Acta Ophthalmologica, 1983 - interscience.wiley.com The toxic effects on rabbit eyes of 2 intravitreally injected fibrinolytic
substances at different concentrations were studied with repeated clinical
observations and registrations of the DC ERG. The fellow, control eye of ... Cited by 3 - Related articles - All 2 versions
J Zwaan, WB Latimer - Ophthalmic surgery and lasers, 1998 - ncbi.nlm.nih.gov BACKGROUND AND OBJECTIVE: To determine the efficacy of topical tissue
plasminogen activator (tPA) for the resolution of postoperative or inflammatory
intraocular fibrinous exudates. PATIENTS AND METHODS: Each treatment ... Cited by 3 - Related articles - BL Direct - All 2 versions
